• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Spironolactone may be effective in the treatment of acne vulgaris

bySoroush NedaieandAlex Chan
May 25, 2023
in Chronic Disease, Dermatology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Spironolactone showed more effective improvement in acne at 12 and 24 weeks after treatment initiation as compared with the placebo.

Evidence Rating Level:1 (Excellent)

Acne is highly prevalent in adolescents and can persist into adulthood. The first-line management of mild to moderate acne typically involves a combination of topical preparations containing retinoids, benzoyl peroxide, or antibiotics. One-third of patients seeking treatment for acne receive long oral antibiotic rouses (>28 days), which presents a concern for developing antibiotic resistance. Spironolactone, a potassium-sparing diuretic, may be a much-needed alternative to oral antibiotics given its anti-androgenic properties. The Spironolactone for Adult Female Acne (SAFA) trial aimed to assess whether spironolactone improves acne in women compared with placebo.  From 10 centers in England and Wales, 407 eligible women – aged 18 years or over with facial acne for at least six months that warranted treatment with oral antibiotics – were randomly assigned in a 1:1 ratio to receive either 50 mg spironolactone (201 patients) or matched placebo (209 patients) once daily for the first six weeks and then two tablets daily at 6 weeks for a total of 24 weeks. Patients, staff, and investigators were masked to treatment allocations. The primary outcome measure was the 12-week mean Acne-QoL symptom subscale score, with higher scores reflecting improved quality of life. After adjusting for baseline variables, there was a small but statistically significant difference of 1.27 (95% CI 0.07 to 2.46)  in the mean Acne-QoL symptom subscale score favoring the spironolactone group at 12 weeks. At 24 weeks, there was a larger mean difference of 3.45 (2.16 to 4.75), representing a statistically significant greater improvement in the spironolactone group. Furthermore, both clinicians and participants were more likely to report overall acne improvement from baseline than those in the placebo group. However, the spironolactone group experienced a higher incidence of adverse reactions, with headaches and dizziness mainly accounting for this difference. Overall,  women reported significant improvements in acne when taking spironolactone as compared to placebo. These findings suggest that spironolactone may be a safe and effective alternative to oral antibiotics for adult women with persistent acne. 

Click to read the study in BMJ

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Remibrutinib alleviates symptoms in chronic spontaneous urticaria resistant to H1-antihistamines

Spironolactone ineffective for patients with preserved ejection fraction after myocardial infarction

Neoadjuvant ipilimumab plus nivolumab improves event-free survival in stage III melanoma

Tags: acneacne vulgarisdermatologyspironolactone
Previous Post

Quizartinib improves overall median survival in patients with acute myeloid leukemia

Next Post

Yoga may improve markers of frailty in older adults

RelatedReports

Rapid growth of medical artificial intelligence technology usage identified from insurance claims analysis, yet major barriers to widespread adoption remain
Chronic Disease

Remibrutinib alleviates symptoms in chronic spontaneous urticaria resistant to H1-antihistamines

March 13, 2025
Cardiology

Spironolactone ineffective for patients with preserved ejection fraction after myocardial infarction

March 4, 2025
Increased risk of subsequent melanoma after first melanoma diagnosis
Dermatology

Neoadjuvant ipilimumab plus nivolumab improves event-free survival in stage III melanoma

December 12, 2024
No difference in PET-CT surveillance versus planned neck dissection in advanced head and neck cancer
Chronic Disease

Use of certain biologics or disease modifying antirheumatic drugs may be associated with cancer risk

November 30, 2024
Next Post

Yoga may improve markers of frailty in older adults

#VisualAbstract: Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

#VisualAbstract: Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

#VisualAbstract: Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

#VisualAbstract: Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Oral vancomycin may be effective for pouchitis in inflammatory bowel disease
  • Inebilizumab improves outcome in patients generalized myasthenia gravis
  • Medbridge turns any phone into a motion-capture coach for at-home rehab
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.